Fidelity Investments’s Connect Biopharma Holdings CNTB Stock Holding History

Fidelity Investments’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-23	Closed	-$28	–	5405
2023 Q4	$27	Sell	23 -1	-4%	-$1	﹤0.01%	5132
2023 Q3	$18	Hold	24	–	–	﹤0.01%	5099
2023 Q2	$26	Sell	24 -9	-27%	-$10	﹤0.01%	5125
2023 Q1	$33	Sell	33 -50	-60%	-$55	﹤0.01%	5025
2022 Q4	$72	Sell	83 -4	-5%	-$3	﹤0.01%	4909
2022 Q3	$0	Sell	87 -97	-53%	-$117	﹤0.01%	4906
2022 Q2	$0	Sell	184 -2,283,085	-100%	-$3.36M	﹤0.01%	4968
2022 Q1	$6.89M	Sell	2,283,269 -1,134,295	-33%	-$4.79M	﹤0.01%	2263
2021 Q4	$17.6M	Sell	3,417,564 -1,400,625	-29%	-$15.6M	﹤0.01%	1890
2021 Q3	$115M	Buy	4,818,189 +892,353	+23%	+$20.2M	0.01%	1038
2021 Q2	$76.7M	Buy	3,925,836 +740,847	+23%	+$12.4M	0.01%	1240
2021 Q1	$58.9M	Buy	+3,184,989	New	+$54.2M	0.01%	1315

Other funds holding CNTB

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

KMWM

Keudell/Morrison Wealth Management Salem, Oregon $529M AUM

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments's CNTB Position: Q1 2024 in Review

Fidelity Investments sold out of Connect Biopharma Holdings (CNTB) in Q1 2024, closing a stake of 23 shares — an estimated $28 sold.

Fidelity Investments first reported a position in CNTB in Q1 2021 and held it in 12 quarters. The position peaked at $115M in Q3 2021. 12 funds tracked by Wall St. Rank hold CNTB as of Q1 2024.

Fidelity Investments reported no remaining Connect Biopharma Holdings position as of Q1 2024 after selling out during the quarter.
Fidelity Investments sold 23 Connect Biopharma Holdings shares in Q1 2024, an estimated $28.
Fidelity Investments first reported a position in Connect Biopharma Holdings in Q1 2021 and held it in 12 quarters.
Fidelity Investments's Connect Biopharma Holdings position peaked at $115M in Q3 2021.
12 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2024.

Based on Fidelity Investments's 13F filing for Q1 2024, filed 13 May 2024.